SCHEMBL30749110

SCHEMBL30749110

O=C1N(c2ccc(N3CCOCC3)cc2)c2nc(CO)nc(C(F)F)c2C12CCCC2

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.33
KDM4E B2RXH2 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
SYK P43405 2/20 0.32
SRC P12931 1/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
PIK3CB P42338 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
CFTR P13569 2/20 0.32
CYP2C19 P33261 1/20 0.32
TNKS O95271 1/20 0.31
TNKS2 Q9H2K2 1/20 0.31
TRPV1 Q8NER1 1/20 0.31
GSK3B P49841 1/20 0.31
RORC P51449 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CTSL P07711 1/20 0.31
CTSB P07858 1/20 0.31
CTSS P25774 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30748928 0.86 MAPT (0.34) MAPTKDM4EMEN1KMT2ASYK
SCHEMBL30749074 0.85 L3MBTL1 (0.35) MAPTSYKL3MBTL1
SCHEMBL31691226 0.84 TNKS (0.30) TNKSTNKS2
SCHEMBL30748855 0.82 SYK (0.39) MAPTMEN1KMT2ASYK
SCHEMBL30749021 0.78 CCNE1 (0.36) MEN1KMT2ASYKCFTRCYP2C19
SCHEMBL30749140 0.75 MAPT (0.39) MAPTKDM4EMEN1KMT2AL3MBTL1
SCHEMBL30748933 0.74 SYK (0.40) MAPTKDM4ESYKL3MBTL1SMN1; SMN2
SCHEMBL30748754 0.74 XDH (0.36) MAPTKDM4EMEN1KMT2AL3MBTL1
SCHEMBL30748888 0.74 CCNE1 (0.39) MAPTKDM4EMEN1KMT2ASYK
SCHEMBL30748964 0.73 CCNE1 (0.37) MAPTMEN1KMT2ASYKTRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT MAPT 3029/4885KDM4E 2102/4885MEN1 301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.